Paper528373
Tetrahydropyranyl derivatives of daunomycin and adriamycin.
Umezawa H and 7 others. J Antibiot (Tokyo), 1979. Cited by 176 papers, by iCite.
Cite this record
ConductScience Library. Tetrahydropyranyl derivatives of daunomycin and adriamycin. Papers, record 528373. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/528373
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Daunorubicin | Major topic |
| Doxorubicin | Major topic |
| Animals | |
| Antibiotics, Antineoplastic | |
| Leukemia L1210 | |
| Mice |
Source PubMed
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 176 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41872646 | Mechanistic Insights into pH-Responsive Drug Release and Antitumor Effects of an Albumin-Pirarubicin Conjugate. | Pharm Res | 2026 | https://conductscience.org/library/papers/41872646 | PubMed |
| 41514559 | Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514559 | PubMed |
| 40205399 | Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study. | BMC Urol | 2025 | https://conductscience.org/library/papers/40205399 | PubMed |
| 40024743 | Prognostic predictors of newly diagnosed Diffuse large B-cell lymphoma treated with R-THP-COP regimen. | J Clin Exp Hematop | 2025 | https://conductscience.org/library/papers/40024743 | PubMed |
| 39941040 | Design of New Daunorubicin Derivatives with High Cytotoxic Potential. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39941040 | PubMed |
| 37238419 | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report. | Children (Basel) | 2023 | https://conductscience.org/library/papers/37238419 | PubMed |
| 37205905 | Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37205905 | PubMed |
| 36575000 | A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma. | J Clin Exp Hematop | 2022 | https://conductscience.org/library/papers/36575000 | PubMed |
| 34193755 | A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma. | J Clin Exp Hematop | 2021 | https://conductscience.org/library/papers/34193755 | PubMed |
| 33864237 | Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry. | Int J Hematol | 2021 | https://conductscience.org/library/papers/33864237 | PubMed |
| 33396604 | Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/33396604 | PubMed |
| 32907549 | Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32907549 | PubMed |
| 31138757 | Low concentration of rutin treatment might alleviate the cardiotoxicity effect of pirarubicin on cardiomyocytes via activation of PI3K/AKT/mTOR signaling pathway. | Biosci Rep | 2019 | https://conductscience.org/library/papers/31138757 | PubMed |
| 28824057 | 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. | Intern Med | 2017 | https://conductscience.org/library/papers/28824057 | PubMed |
| 27858183 | Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study. | Int J Clin Oncol | 2017 | https://conductscience.org/library/papers/27858183 | PubMed |
| 25529761 | Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin. | Cancer Sci | 2015 | https://conductscience.org/library/papers/25529761 | PubMed |
| 25432694 | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? | Med Oncol | 2015 | https://conductscience.org/library/papers/25432694 | PubMed |
| 22580740 | Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. | Acta Pharmacol Sin | 2012 | https://conductscience.org/library/papers/22580740 | PubMed |
| 20033628 | Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. | Int J Hematol | 2010 | https://conductscience.org/library/papers/20033628 | PubMed |
| 19707675 | Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics. | Org Biomol Chem | 2009 | https://conductscience.org/library/papers/19707675 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/528373
GET https://conductscience.org/api/papers/v1/528373/cited_by?page=2